Piramal Life Sciences Begins Diabetes Drug Trial

by Rajashri on  May 20, 2009 at 9:13 PM Corporate News   - G J E 4
 Piramal Life Sciences Begins Diabetes Drug Trial
Piramal Life Sciences announced today that it was beginning a Phase I trial for a diabetes-metabolic syndrome drug called as molecule P2202.

This trial is using the second molecule from US-based Eli Lilly Co, which has an agreement with Piramal for developing such drugs.

"This is our eighth entity to enter the clinic and third for diabetes-metabolic disorders and bears testimony to our efforts to build a diversified and strong pipeline of products to address unmet medical needs in this important therapeutic segment," said Piramal Managing Director Somesh Sharma.

Piramal Life also added that Health Canada had already given regulatory approval for the trial.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like